Christopher Rovaldi - 01 Feb 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Reporting relationship: Chief Operating Officer
Issuer ticker: KROS
Reported as of: 01 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2022, 15:45:42 UTC
Next SEC filing: 05 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Esther Cho, Attorney-in-Fact

Key filing fact

Christopher Rovaldi filed Form 4 for Keros Therapeutics, Inc. (KROS) on 03 Feb 2022.

Key facts

This page summarizes Christopher Rovaldi's Form 4 filing for Keros Therapeutics, Inc. (KROS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2022, 15:45.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KROS transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 01 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $49.34
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-fourth (1/4th) of the shares subject to the option shall vest on February 1, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.